MGNX Macrogenics Inc
4,199
$4.70
$0.44
(10.33%)
| Watchers | 4,199 |
| 52-Wk Low | $3.14 |
| 52-Wk High | $21.88 |
| Market Cap | $266.82M |
| Volume | 78.00 |
| 52-Wk High | $21.88 |
| 52-Wk Low | $3.14 |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXPR Newswire • about 14 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
Share to Feed
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment PR Newswire...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm INVESTIGATION ALERT: The Schall Law Firm Announces...
The law firm of Kirby McInerney LLP is investigating potential claims against MacroGenics, Inc. (MacroGenics or the Company) (NASDAQ: MGNX). The investigation concerns whether MacroGenics and/or...
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.
Latest Ratings for MGNX
DateFirmActionFromTo Feb...
"Worst Case Scenario": MacroGenics Crashes After Five Patient Deaths In Experimental Drug Trial
A Rockville, Maryland-based biotech company called MacroGenics crashed in premarket...
Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 in metastatic prostate cancer. Despite responses, notable safety...
US Futures, Global Markets Storm Higher, Eye All-Time Highs
US equity futures pointed to even more gains on the last day of trading, leaving the S&P 500 set for a third weekly rise the...
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 PR Newswire VANCOUVER, BC, May 1, 2024 USA News Group Commentary...